Ilyang Pharm confirms effect of treating Parkinson’s disease treatment from leukemia treatment ‘Supect’

Published: 2017-08-04 16:26:00
Updated: 2017-08-04 13:30:57

‘Radotinib(product name: Supect),’ a leukemia treatment developed by Ilyang Pharmaceutical, showed a clinical trial result that it had an effect of treating ‘Parkinson’s disease’ as well.

Ilyang Pharm announced on the 26th that a research team at Johns Hopkins University conducted mechanism, cel...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.